NCT06981195View on ClinicalTrials.gov

Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 27, 2025

Primary Completion Date

July 30, 2029

Study Completion Date

July 30, 2029

Conditions
Opioid Use DisorderOpioid UseInsomniaOrexin Antagonist
Interventions
DRUG

Placebo

Subjects who are randomized to placebo will receive identical capsules to the study drug. During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed

DRUG

Lemborexant 10 MG

During the 8-week intervention phase, participants will be instructed to take one capsule daily, approximately 5-30 minutes before going to bed

Trial Locations (1)

23219

RECRUITING

VCU Institute for Drug and Alcohol Studies, Richmond

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Virginia Commonwealth University

OTHER

NCT06981195 - Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects | Biotech Hunter | Biotech Hunter